RxSight (RXST) Competitors

RxSight (NASDAQ:RXST) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.

Is RXST or ENOV more profitable?

Enovis has a net margin of -5.95% compared to RxSight's net margin of -23.92%. Enovis' return on equity of 4.39% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-23.92%	-14.00%	-12.51%
Enovis	-5.95%	4.39%	2.80%

Does the media favor RXST or ENOV?

In the previous week, RxSight had 9 more articles in the media than Enovis. MarketBeat recorded 17 mentions for RxSight and 8 mentions for Enovis. RxSight's average media sentiment score of 1.48 beat Enovis' score of 1.10 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend RXST or ENOV?

RxSight presently has a consensus price target of $37.90, indicating a potential upside of 136.73%. Enovis has a consensus price target of $58.00, indicating a potential upside of 78.95%. Given RxSight's higher probable upside, equities analysts plainly believe RxSight is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Enovis	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the MarketBeat Community favor RXST or ENOV?

RxSight received 17 more outperform votes than Enovis when rated by MarketBeat users. However, 66.04% of users gave Enovis an outperform vote while only 63.41% of users gave RxSight an outperform vote.

Company	Underperform	Outperform
RxSight	Outperform Votes 52 63.41%	Underperform Votes 30 36.59%
Enovis	Outperform Votes 35 66.04%	Underperform Votes 18 33.96%

Do insiders & institutionals believe in RXST or ENOV?

78.8% of RxSight shares are held by institutional investors. Comparatively, 98.4% of Enovis shares are held by institutional investors. 9.4% of RxSight shares are held by company insiders. Comparatively, 2.7% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has stronger earnings & valuation, RXST or ENOV?

Enovis has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$148.31M	4.39	-$48.61M	-$0.67	-23.90
Enovis	$2.15B	0.86	-$33.26M	-$13.95	-2.32

Which has more volatility & risk, RXST or ENOV?

RxSight has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.

Summary

Enovis beats RxSight on 10 of the 18 factors compared between the two stocks.